Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) accounts for up to 95% of all pancreatic cancer cases and is the seventh-leading cause of cancer death. Poor prognosis is a result of late presentation, a lack of screening tests and the fact some patients develop resistance to chemotherapy and radiotherapy. N...

Full description

Bibliographic Details
Main Authors: Tarak Chouari, Francesca Soraya La Costa, Nabeel Merali, Maria-Danae Jessel, Shivan Sivakumar, Nicola Annels, Adam E. Frampton
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
pancreatic ductal adenocarcinoma
immunotherapy
pancreas
vaccination therapies
oncolytic viral therapy
Online Access:https://www.mdpi.com/2072-6694/15/17/4265

Internet

https://www.mdpi.com/2072-6694/15/17/4265

Similar Items